PCM
ACHN

Parsons Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Parsons Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,000
Closed -$30K – 558
2015
Q1 		$30K Buy
+3,000
New +$37.5K ﹤0.01% 540

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parsons Capital Management's ACHN Position: Q2 2015 in Review

Parsons Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 3,000 shares — an estimated $30K sold.

Parsons Capital Management first reported a position in ACHN in Q1 2015 and held it in 1 quarter. The position peaked at $30K in Q1 2015. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Parsons Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Parsons Capital Management sold 3,000 Achillion Pharmaceuticals shares in Q2 2015, an estimated $30K.
  • Parsons Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Parsons Capital Management's Achillion Pharmaceuticals position peaked at $30K in Q1 2015.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Parsons Capital Management's 13F filing for Q2 2015, filed 5 Aug 2015.